358 related articles for article (PubMed ID: 28412197)
1. An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients.
Rousset M; Titier K; Bouchet S; Dutriaux C; Pham-Ledard A; Prey S; Canal-Raffin M; Molimard M
Clin Chim Acta; 2017 Jul; 470():8-13. PubMed ID: 28412197
[TBL] [Abstract][Full Text] [Related]
2. Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E; Mercier T; Wagner AD; Homicsko K; Michielin O; Ellefsen-Lavoie K; Cagnon L; Diezi M; Buclin T; Widmer N; Csajka C; Decosterd L
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1083():124-136. PubMed ID: 29544202
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry.
Nijenhuis CM; Haverkate H; Rosing H; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2016 Jun; 125():270-9. PubMed ID: 27058232
[TBL] [Abstract][Full Text] [Related]
4. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
5. [Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].
Sibaud V; Baric L; Cantagrel A; Di Palma M; Ederhy S; Paques M; Perlemuter G
Bull Cancer; 2021 May; 108(5):528-543. PubMed ID: 33812673
[TBL] [Abstract][Full Text] [Related]
6. The new paradigm of systemic therapies for metastatic melanoma.
Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
[TBL] [Abstract][Full Text] [Related]
7. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
8. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma.
Sengul Samanci N; Çelik E; Bagcilar O; Erol BC; Bicki E; Oruc K; Bedir S; Degerli E; Derin S; Demirci NS; Demirelli FH
Melanoma Res; 2020 Oct; 30(5):477-483. PubMed ID: 32898388
[TBL] [Abstract][Full Text] [Related]
9. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Daud A; Tsai K
Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
[TBL] [Abstract][Full Text] [Related]
10. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
11. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
Daud A; Gill J; Kamra S; Chen L; Ahuja A
J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
[TBL] [Abstract][Full Text] [Related]
12. BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation.
Hoyer S; Eberlein V; Schuler G; Berking C; Heinzerling L; Schaft N; Dörrie J
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769379
[TBL] [Abstract][Full Text] [Related]
13. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma.
Nijenhuis CM; Rosing H; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2014 Jan; 88():630-5. PubMed ID: 24216282
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
16. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
[TBL] [Abstract][Full Text] [Related]
17. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
Jarkowski A; Norris L; Trinh VA
Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
Guha A; Jain P; Fradley MG; Lenihan D; Gutierrez JM; Jain C; de Lima M; Barnholtz-Sloan JS; Oliveira GH; Dowlati A; Al-Kindi S
Cancer Med; 2021 Jun; 10(12):3862-3872. PubMed ID: 33982883
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
Kawaguchi K; Murakami T; Chmielowski B; Igarashi K; Kiyuna T; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM
Oncotarget; 2016 Nov; 7(44):71737-71743. PubMed ID: 27690220
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF
Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]